ArticleJournal of neuro-oncology2026
The persistent benefit of chemotherapy in elderly lung adenocarcinoma patients with brain metastases in the immunotherapy era.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNivolumab was first approved to treat patients with advanced non-small cell lung cancer (NSCLC) in 2015. Since then, NSCLC treatment has entered the immunotherapy era. However, studies on the effect of chemotherapy in the immunological era on elderly lung adenocarcinoma (LUAD) patients with brain metastases are lacking. This study aimed to analyze the effect of chemotherapy on the overall survival (OS) of elderly LUAD patients with brain metastases in the immunotherapy era.
methodsThis study included elderly patients (≥ 80 years) diagnosed with LUAD and brain metastases in the Surveillance, Epidemiology, and End Results (SEER) database from 2015 to 2021. Patients were divided into chemotherapy and non-chemotherapy groups. Propensity score matching (PSM) was utilized to reduce bias between two groups. Survival analyses were performed using Kaplan-Meier curves and Cox regression models.
resultsMultivariate analysis revealed that chemotherapy (HR 0.366; 95% CI 0.325-0.412; P < 0.001) was an independent prognostic factor affecting OS for elderly LUAD patients with brain metastases in the era of immunotherapy. Survival analysis showed that the median OS was higher in the chemotherapy group than in the non-chemotherapy group (10 months vs. 2 months) before and after PSM. Subgroup analysis indicated that the risk of death was lower in the group that received chemotherapy compared to the group that did not receive chemotherapy, particularly in patients with T3-4, N2-3, bone metastases, liver metastases, and lung metastases.
conclusionsChemotherapy may still be indispensable for patients with advanced LUAD and brain metastases in the era of immunotherapy.
Indexed as
Identifiers
42481787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.